Amyloidosis Awareness Month offers an opportunity to spotlight this rare disease and those patients who struggle to obtain diagnosis and treatment. The condition is characterized by misfolded amyloid proteins that build up in the heart and other organs, disrupting their function. It is notoriously difficult to diagnose because its symptoms can vary so widely to include fatigue, swelling, kidney and nerve damage. Early detection is essential because disease progression can result in disability or death.
Amyloidosis can be hereditary or can develop naturally. Even though the disease is classified as rare, its prevalence in the African American community is disproportionately high. That higher rate of occurrence coincides with statistically worse access to health resources and prompt treatment, leading to inequitable outcomes across patient populations.
Innovation Rises, Access Lags
Amyloidosis Awareness Month also encourages innovation of emerging treatments, improving the outlook for many patients. New diagnostic techniques are more accurate, and new treatments are known to reduce hospitalization, protect organs and extend survival. Care by specialists familiar with amyloidosis presentation and treatments can also play a key role in preventing the progression of the disease.
As in many other areas, however, unequal access to care and poor insurance coverage stratifies experiences within the health system. Amyloidosis patients who do not have access to specialized care, because of financial or geographic challenges, have statistically worse outcomes. Treatment can be very expensive, so lower-income populations have fewer options and may face interference from insurance companies.
“Patients who don’t have access, who don’t get specialty care often have delayed diagnosis and delayed diagnosis increases hospitalization and mortality,” according to Dr. Keith Ferdinand, professor of medicine at Tulane University.
These dangerous discrepancies underscore the simple truth that better health outcomes depend not only on scientific innovation, but on access. Equipping clinicians and reducing barriers to care can improve the experiences and outcomes of those living with amyloidosis.
